J Urol 1997;158:1722C7

J Urol 1997;158:1722C7. from your same 56 individuals also reacted. In contrast, 25/72 (35%) samples of GIM from individuals in group B reacted with mAb Das-1 (group A B, p<0.0001). None of the samples from group C reacted with the mAb. Conclusions: Reactivity of mAb YZ9 Das-1 is definitely clinically useful to YZ9 simplify and differentiate the phenotypes of GIM. The colonic phenotype of GIM, as recognized by mAb Das-1, is definitely strongly associated with gastric carcinoma. Keywords: monoclonal antibody, Das-1, colonic-type metaplasia, gastric carcinogenesis Morphological changes in the mucosa of the belly, resembling that of the intestine, constitute the condition known as intestinal metaplasia. Gastric intestinal metaplasia (GIM) is not a single entity but rather a heterogeneous group of metaplastic changes.1 Matsukura divided GIM into total (small intestinal) and incomplete (colonic) varieties using enzyme techniques.2 Another classification categorised GIM into three types: I (complete), and II and III (incomplete).3 This is based on the fact that small intestinal goblet cells produce sialoglycoprotein that stains with periodic acid-Schiff (PAS) and alcian blue (AB), and colonic goblet cells produce sulphomucin that is detected by AB/high iron diamine (HID) staining.1,4,5 Incomplete GIM appears to carry the highest preneoplastic potential for the intestinal variety of gastric carcinoma, which YZ9 is the most common type of gastric carcinoma; even though some studies have also linked total GIM with gastric carcinoma. 6 Using histological and histochemical mucin staining techniques, it has been hard to accurately define the phenotypic differentiation of GIM due to observer dependent variability in identifying subtle colour variations.7 This situation is often further complicated from the coexistence of different types of GIM and the presence of mosaic cases, which have been reported to occur in 41% of individuals. A biomarker(s) to reliably differentiate various types of GIM, and determine individuals who may be at a higher risk of developing gastric carcinoma, would be clinically very useful. Using a colon epithelial protein, we developed a novel murine monoclonal antibody, mAb Das-1 (formerly known as 7E12H12, IgM isotype), that reacts with colonic epithelium.8 Using both immunoperoxidase and immunofluorescence assays, we while others have independently demonstrated that mAb Das-1 specifically reacts with colonic epithelium (both goblet and non-goblet absorptive cells) but not with small intestinal enterocytes (including goblet cells) from your jejunum or ileum, or normal epithelium from the rest of the gastrointestinal tract.8,9 Although mAb Das-1 does not react with normal gastric and oesophageal epithelium, it reacts sensitively (95%) and specifically (100%) with Barretts epithelium and adenocarcinoma of the oesophagus, indicating a strong association of its reactivity to this precancerous condition.10,11 In the present study, we explored if mAb Das-1 reactivity helps to identify the colonic phenotype of metaplasia in the belly and its association with gastric carcinoma. We examined the immunoreactivity of the mAb against the YZ9 cells with different histological spectra of chronic gastritis beginning at an early stage before the development of GIM, in the intermediate stage when GIM experienced developed but no malignancy was detectable, and finally in the point where GIM RAF1 was associated with gastric carcinoma. As gastric carcinoma is definitely more common in Japan, we compared the reactivity in the cells specimens from the USA (New Jersey, NJ) and Japan. MATERIALS AND METHODS Paraffin inlayed cells blocks were from 150 individuals from NJ and Japan. Group A (n=60) We used the computer database of the pathology departments to randomly select 60 cells blocks having a analysis of GIM associated with gastric carcinoma. Thirty five individuals from Japan (group A1) and 25 from NJ (group A2) were YZ9 included. For each of these 60 individuals, paired samples of belly (medical specimens) included both malignancy areas and.